Exploiting plasmid–bacteria interactions to fight the evolution of antimicrobial resistance
PLAS-FIGHTER aims to develop innovative strategies against plasmid-mediated antimicrobial resistance by exploring plasmid-induced physiological effects in bacteria using advanced screening and ecological models.
Projectdetails
Introduction
The discovery of antibiotics revolutionised the fight against infectious diseases and paved the way for modern medicine. However, widespread use of antibiotics has driven rampant evolution of antimicrobial resistance (AMR) in bacteria.
Mechanism of AMR Acquisition
The main route for AMR acquisition in clinically important bacteria is the horizontal transfer of plasmids (conjugation-competent mobile genetic elements) carrying resistance genes. AMR plasmids allow bacteria to survive antibiotics, but they also entail physiological alterations in the host cell.
Recent Findings
Recent results from my group and others reveal that AMR plasmids:
- Produce a shared set of physiological alterations in the bacterial host.
- Induce changes in host antibiotic susceptibility profiles.
Project Goals
The goal of PLAS-FIGHTER is to exploit plasmid-induced physiological effects in bacteria to develop new ecology- and evolution-informed strategies against plasmid-mediated AMR.
Objective 1: Dissecting Molecular Basis
First, we will use genome-wide CRISPRi screening technology to dissect the molecular basis and functional consequences of plasmid-induced physiological effects in clinical bacteria at an unprecedented level of resolution, revealing new specific targets in AMR plasmid-carrying cells.
Objective 2: High-Throughput Susceptibility Assays
Second, we will perform high-throughput susceptibility assays, using inhibitors of the targets revealed in the first objective and a wide range of antibiotics in a collection of paired isogenic plasmid-carrying and plasmid-free bacterial strains of the highest clinical relevance.
Experimental Design
Crucially, we will perform experiments and test candidate treatments in a gradient of increasing ecological complexity, in terms both of community composition (from monocultures to human gut communities) and habitat structure (from in vitro lab cultures to the mouse gut).
Conclusion
In PLAS-FIGHTER, I will build on my established expertise and pioneering results to develop a novel, multidisciplinary, ground-breaking project that will open up new research avenues towards ecology- and evolution-informed anti-AMR strategies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.999.573 |
Totale projectbegroting | € 1.999.573 |
Tijdlijn
Startdatum | 1-2-2024 |
Einddatum | 31-1-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Antibiotics of the future: are they prone to bacterial resistance?This project aims to develop a forecasting framework for the long-term effectiveness of new antibiotics by studying bacterial resistance evolution and its implications for future antibiotic design and use. | ERC Advanced... | € 3.479.716 | 2024 | Details |
Breaking resistance of pathogenic bacteria by chemical dysregulationThe project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy. | ERC Advanced... | € 2.499.785 | 2023 | Details |
Molecular and Genome Evolution of Prokaryotic PlasmidsThe pMolEvol project aims to develop a unified framework for understanding plasmid evolution by quantifying genetic diversity, fitness, and evolutionary patterns using empirical data and genomic reconstruction. | ERC Consolid... | € 2.112.500 | 2023 | Details |
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPRThis project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies. | ERC Consolid... | € 1.999.780 | 2022 | Details |
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistanceAI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance. | ERC Synergy ... | € 10.968.734 | 2025 | Details |
Antibiotics of the future: are they prone to bacterial resistance?
This project aims to develop a forecasting framework for the long-term effectiveness of new antibiotics by studying bacterial resistance evolution and its implications for future antibiotic design and use.
Breaking resistance of pathogenic bacteria by chemical dysregulation
The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.
Molecular and Genome Evolution of Prokaryotic Plasmids
The pMolEvol project aims to develop a unified framework for understanding plasmid evolution by quantifying genetic diversity, fitness, and evolutionary patterns using empirical data and genomic reconstruction.
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR
This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.
Deep learning analysis of imaging and metabolomic data to accelerate antibiotic discovery against antimicrobial resistance
AI4AMR aims to revolutionize antibiotic discovery by using advanced AI and multi-dimensional data analysis to identify novel antibiotics and their mechanisms of action against antimicrobial resistance.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistanceMaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials. | EIC Pathfinder | € 3.194.450 | 2024 | Details |
InnomABsIPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie. | Mkb-innovati... | € 14.888 | 2023 | Details |
Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradicationBactEradiX aims to create a novel antimicrobial nanomaterial targeting biofilm Z-DNA to effectively eradicate chronic infections caused by drug-resistant bacteria. | EIC Pathfinder | € 2.996.312 | 2024 | Details |
Pharmaco-modulation of epithelia for induction of antimicrobial peptide expression: a disruptive approach to fight antibiotic resistance
MaxImmun aims to develop innovative molecules that enhance antimicrobial peptides to combat infections and antibiotic resistance, progressing towards clinical trials.
InnomABs
IPA onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten als alternatief voor antibiotica tegen antimicrobiële resistentie.
Advanced nanomaterials to target genomic and Z-DNA for bacterial biofilm eradication
BactEradiX aims to create a novel antimicrobial nanomaterial targeting biofilm Z-DNA to effectively eradicate chronic infections caused by drug-resistant bacteria.